sever
acut
respiratori
syndrom
sar
emerg
highli
contagi
sometim
fatal
diseas
find
diseasespecif
b
cell
epitop
phagedisplay
random
peptid
librari
pan
serum
immunoglobulin
ig
g
antibodi
patient
sar
fortynin
immunoposit
phage
clone
bound
specif
serum
patient
sar
select
phageborn
peptid
consensu
motif
correspond
amino
acid
sequenc
report
sarsassoci
coronaviru
sarscov
synthet
peptid
bind
competitiveinhibit
assay
confirm
patient
sar
gener
antibodi
sarscov
immunoposit
phage
clone
epitopebas
peptid
antigen
demonstr
clinic
diagnost
potenti
react
serum
patient
sar
antibodyrespons
kinet
evalu
patient
sar
product
igm
igg
iga
document
part
immun
respons
conclus
b
cell
epitop
sar
correspond
novel
coronaviru
epitopebas
serolog
test
may
use
laboratori
detect
viru
studi
pathogenesi
sar
sinc
novemb
case
report
lifethreaten
highli
contagi
febril
respiratori
ill
unknown
etiolog
guangdong
provinc
southern
china
follow
case
report
vietnam
hong
kong
singapor
canada
unit
state
late
februari
ill
identifi
new
clinic
entiti
call
sever
acut
respiratori
syndrom
sar
readi
transmiss
sar
led
outbreak
among
household
member
health
care
worker
also
within
commun
larg
report
indic
sarsassoci
coronaviru
sarscov
human
metapneumoviru
hmpv
might
respons
sar
one
recent
studi
indic
sarscov
fulfil
koch
postul
primari
etiolog
agent
sar
activ
host
humor
immun
viral
infect
trigger
product
antibodi
direct
viral
protein
epitop
knowledg
viral
protein
epitop
pivot
understand
pathogenesi
viral
infect
develop
diagnost
reagent
effect
vaccin
phage
display
use
identifi
immunogen
target
epitop
recogn
antibodi
select
peptid
librari
monoclon
antibodi
complex
serum
patient
diseas
led
isol
immunoreact
peptid
epitop
diseasespecif
epitop
use
develop
diagnost
prevent
reagent
identifi
screen
phagedisplay
peptid
librari
serum
cerebrospin
fluid
sampl
patient
viral
infect
rheumatoid
arthriti
multipl
sclerosi
autoimmun
phagedisplay
peptidelibrari
screen
serum
sampl
patient
sever
acut
respiratori
syndrom
sar
illustr
principl
select
sarsspecif
epitop
use
studi
phagedisplay
peptid
librari
preclear
use
normal
human
serum
affin
select
serum
antibodi
ab
patient
sar
biopan
time
immunoposit
phage
clone
select
elisa
diseasespecif
epitop
identifi
character
synthet
peptid
bind
competitiveinhibit
assay
phagedisplay
diseasespecif
epitop
use
determin
microbiolog
origin
studi
immunotyp
provid
inform
develop
diagnost
reagent
vaccin
b
select
phagedisplay
peptid
librari
immunoglobulin
purifi
serum
sampl
patient
third
round
biopan
mark
enrich
evid
compar
first
round
select
ag
antigen
pfu
plaqueform
unit
thrombocytopen
purpura
neurocysticercosi
identifi
peptid
correspond
mimick
natur
epitop
appli
phagedisplay
technolog
character
specif
antibodi
present
serum
sampl
patient
sar
result
studi
contribut
develop
sensit
simpl
test
diagnosi
sar
help
investig
pathogenesi
sar
identifi
treat
nation
taiwan
univers
hospit
ntuh
taipei
serum
sampl
patient
sent
hospit
depart
laboratori
medicin
routin
serolog
biochem
analysi
laboratori
diagnost
test
clinic
manifest
ill
treatment
patient
describ
detail
recent
publish
report
serum
sampl
collect
patient
sar
test
use
follow
method
viru
isol
vero
cell
american
type
cultur
collect
serotypespecif
reversetranscriptas
rt
polymeras
chain
reaction
pcr
standard
indirect
fluoresc
antibodi
ifa
assay
de
identif
serum
antibodyselect
phage
clone
elisa
serum
sampl
patient
sever
acut
respiratori
syndrom
phagedisplay
random
peptid
librari
screen
serum
antibodi
patient
screen
round
phage
clone
select
phage
clone
significantli
reactiv
antibodi
serum
sampl
patient
sampl
normal
human
serum
b
od
optic
densiti
nm
tection
antibodi
sarscov
patient
sar
posit
sar
rna
rtpcr
posit
sar
antibodi
ifa
assay
patient
seroneg
although
patient
receiv
ribavirin
corticosteroid
intraven
immunoglobulin
treatment
earli
stage
diseas
antibodi
detect
ifa
assay
earli
day
onset
ill
written
inform
consent
obtain
volunt
studi
approv
ethic
committe
colleg
medicin
nation
taiwan
univers
taipei
human
experiment
guidelin
us
depart
health
human
servic
follow
conduct
research
affin
select
phage
biopan
protein
g
magnet
microbead
dynabead
protein
g
dynal
use
purifi
igg
serum
sampl
patient
sar
enhanc
select
peptid
bind
igg
specif
associ
patient
sar
design
preclear
step
remov
nonspecif
clone
preabsorpt
phagedisplay
peptid
librari
phage
parti
cle
new
england
biolab
onto
purifi
igg
normal
serum
pool
control
subject
sarscov
seroneg
ifa
assay
blood
donor
next
preclear
phage
librari
select
onto
igg
purifi
serum
patient
sar
affin
select
immobil
igg
serum
patient
sar
h
use
screen
unbound
phage
particl
remov
magnet
bead
wash
extens
pbst
pb
plu
wtvol
bound
phage
particl
elut
glycin
buffer
ph
neutral
tri
buffer
ph
amplifi
subsequ
round
select
three
round
select
perform
patient
biopan
protocol
second
third
round
ident
first
round
addit
pfu
phage
par
ticl
biopan
titrat
unamplifi
thirdround
phage
eluat
done
luria
brothisopropyl
plate
falcon
becton
dickinson
remain
eluat
store
identif
immunoposit
phage
clone
elisa
elisa
plate
coat
mgml
purifi
antihuman
igg
captur
antibodi
jackson
immunoresearch
lab
moll
nahco
ph
room
temperatur
h
consensu
amino
acid
indic
boldfac
type
block
pbsb
bovin
serum
albumin
pb
overnight
serial
dilut
phage
particl
ad
plate
coat
serum
antibodi
patient
incub
room
temperatur
h
plate
wash
time
pbst
dilut
horseradish
peroxidas
hrp
conjug
antibodi
pharmacia
product
ad
plate
incub
room
temperatur
h
agit
wash
time
pbst
color
subsequ
develop
dark
ophenylenediamin
dihydrochlorid
sigma
hydrogen
peroxid
reaction
stop
n
hcl
absorb
measur
nm
use
elisa
reader
versa
max
tunabl
micropl
reader
molecular
devic
immunoposit
phage
clone
character
dna
sequenc
accord
method
describ
elsewher
dna
sequenc
comput
analysi
dna
sequenc
purifi
phage
clone
determin
accord
dideoxynucleotid
chaintermin
method
use
autom
dna
sequenc
abi
prism
perkinelm
primer
use
phage
dna
sequenc
ccctcatag
tabl
align
phagedisplay
peptid
sequenc
complet
genom
sever
acut
respiratori
syndromeassoci
coronaviru
sarscov
peptid
sequenc
peptid
sequenc
sarscov
retriev
genbank
access
no
phagedisplayedconsensu
amino
acid
indic
boldfac
type
peptid
sequenc
correspond
amino
acid
gene
b
peptid
sequenc
correspond
amino
acid
gene
primer
locat
antisens
strand
gene
iii
phage
separ
insert
dna
nt
insert
oligonucleotid
sequenc
phage
dna
select
translat
peptid
sequenc
peptid
sequenc
align
use
macdnasi
softwar
hitachi
softwar
engin
align
phagedisplay
peptid
sequenc
publish
protein
sequenc
sever
virus
includ
sarscov
dengu
viru
japanes
enceph
viru
hmpv
human
rhinoviru
type
human
enteroviru
type
respiratori
syncyti
viru
influenza
viru
retriev
genbank
access
no
respect
competitiveinhibit
assay
immunoposit
phage
particl
incub
individu
peptid
antigen
control
peptid
transfer
antibodyco
plate
incub
h
plate
incub
hrpconjug
antibodi
procedur
describ
follow
detect
serum
sampl
patient
sar
use
immunoposit
phage
clone
elisa
plate
coat
mgml
purifi
antihuman
igm
antihuman
igg
captur
antibodi
jackson
immunoresearch
lab
block
pbsb
incub
test
serum
sampl
dilut
room
temperatur
h
ad
immunoposit
phage
particl
antibodyco
plate
plate
wash
time
pbst
procedur
describ
follow
detect
serum
sampl
patient
sar
use
epitopebas
synthet
peptid
elisa
plate
coat
mgml
individu
peptid
antigen
mlwell
incub
h
wash
pbst
pb
plu
wtvol
plate
block
pbsb
overnight
incub
test
serum
sampl
dilut
room
temperatur
h
hrpconjug
goat
antihuman
igg
jackson
patient
serum
antibodi
control
subject
b
analysi
serum
patient
sar
normal
serum
healthi
subject
serum
sampl
incub
pfu
immunoposit
phage
clone
immunoposit
phage
clone
highli
reactiv
serum
patient
sar
serum
healthi
subject
od
optic
densiti
nm
immunoresearch
lab
dilut
ad
microtit
plate
follow
procedur
describ
patient
first
document
case
patient
sar
taiwan
develop
febril
ill
admit
ntuh
march
patient
convalesc
serum
sampl
collect
april
studi
diseasespecif
epitop
sar
select
immunoposit
phage
clone
sarsspecif
serum
antibodi
done
immobil
protein
g
magnet
bead
bound
phage
clone
select
biopan
enhanc
select
peptid
bind
igg
specif
associ
patient
sar
design
preclear
select
procedur
see
materi
method
strategi
identif
sarsspecif
epitop
shown
figur
mark
enrich
log
scale
much
follow
third
round
select
compar
first
round
select
figur
individu
phage
clone
third
round
biopan
randomli
select
elisa
perform
determin
whether
antibodi
present
serum
sampl
patient
specif
recogn
select
phage
clone
deriv
biopan
select
phage
clone
signific
enhanc
bind
activ
sarsspecif
serum
antibodi
figur
clone
bind
normal
human
serum
figur
identif
sarsspecif
b
cell
epitop
fortynin
immunoposit
phage
clone
highli
reactiv
sarsspecif
serum
antibodi
less
reactiv
antibodi
normal
serum
amplifi
phage
dna
isol
sequenc
insert
nucleotid
select
phage
clone
sequenc
contain
nt
translat
aa
residu
tabl
peptid
sequenc
align
use
macdnasi
softwar
analyz
epitop
bind
motif
sar
antibodi
immunoposit
clone
obtain
bind
motif
tabl
align
phagedisplay
peptid
sequenc
complet
genom
sever
virus
describ
materi
method
show
bind
motif
highli
conserv
mani
immunoposit
phage
clone
correspond
exactli
amino
acid
residu
sarscov
tabl
tivaklr
tabl
similar
amino
acid
residu
hmpv
lsplgalvacyk
consensu
sequenc
indic
boldfac
type
prove
select
phage
clone
bound
specif
serum
patient
sar
antibodi
patient
sar
healthi
control
subject
incub
serial
dilut
immunoposit
phage
clone
bound
serum
patient
sar
specif
dose
depend
two
control
serum
sampl
react
figur
confirm
select
phage
clone
specif
bound
serum
patient
sar
immunoposit
phage
clone
incub
serum
sampl
patient
sar
serum
sampl
healthi
control
subject
elisa
indic
immunoposit
phage
clone
high
antibodi
specif
phage
clone
figur
three
phage
clone
highli
reactiv
serum
sampl
patient
sar
none
phage
clone
react
serum
sampl
healthi
control
subject
figur
verifi
peptid
sequenc
identifi
phage
display
recogn
sarsspecif
serum
antibodi
perform
synthet
peptidebind
assay
phagedisplay
peptid
synthes
multipleantigen
peptid
map
form
elisa
sensit
map
greater
singlechain
peptid
shown
figur
synthet
peptid
vkipqhmhplpi
vkppnprptmslw
vkidnaspa
correspond
immunoposit
phage
clone
amino
acid
residu
sarscov
bound
antibodi
concentrationdepend
manner
unrel
control
map
slhntmpse
reactiv
confirm
phagedisplay
peptid
epitop
sarsspecif
serum
antibodi
peptid
competitiveinhibit
assay
perform
determin
whether
synthet
peptid
select
phage
clone
compet
antibodybind
site
bind
activ
sarsspecif
serum
antibodi
phage
clone
inhibit
synthet
peptid
dosedepend
manner
arbitrari
control
peptid
slhntmpse
effect
abil
phage
particl
bind
sarsspecif
serum
antibodi
figur
one
microgram
per
millilit
peptid
inhibit
phageclon
bind
sarsspecif
serum
antibodi
bind
phage
clone
sarsspecif
serum
antibodi
also
inhibit
synthet
peptid
dosedepend
manner
one
microgram
per
millilit
peptid
inhibit
phageclon
bind
sarsspecif
serum
antibodi
figur
synthet
peptid
vkidnaspa
correspond
amino
acid
residu
sarscov
bound
antibodi
concentrationdepend
manner
figur
confirm
phagedisplay
peptid
epitop
sarsspecif
serum
antibodi
peptid
competitiveinhibit
assay
conduct
determin
whether
peptid
phage
clone
compet
antibodybind
site
result
indic
bind
activ
sarsspecif
serum
antibodi
phage
clone
inhibit
dosedepend
manner
one
microgram
per
millilit
peptid
inhibit
phageclon
bind
sarsspecif
serum
antibodi
wherea
arbitrari
control
peptid
slhntmpse
effect
figur
confirm
epitopebas
synthet
peptid
gener
antibodi
sarscov
immun
balbc
mice
peptid
serum
sampl
mice
found
elisa
gener
antibodi
correspond
peptid
antigen
figur
four
mice
mice
found
ifa
assay
gener
antibodi
recogn
sarscovinfect
vero
cell
antibodi
titer
figur
peptid
competit
inhibit
antibodi
bind
sarscov
figur
panel
b
f
respect
unrel
control
peptid
slhntmpse
effect
figur
panel
c
g
normal
mous
serum
reactiv
figur
panel
detect
serum
sampl
patient
sar
use
epitopebas
peptid
antigen
evalu
whether
epitopebas
peptid
antigen
immunoposit
phage
clone
synthet
peptid
could
use
diagnost
reagent
detect
serum
sampl
patient
sar
march
may
collect
serum
sampl
patient
ill
met
cdc
case
definit
probabl
sar
test
detect
efficaci
peptid
antigen
patient
convalesc
serum
sampl
obtain
day
diseas
onset
patient
serum
sampl
obtain
day
respect
onset
ill
diagnos
sar
test
serum
sampl
phage
clone
use
igmor
iggcaptur
elisa
result
indic
sampl
patient
detect
posit
igmcaptur
elisa
figur
sampl
patient
detect
posit
iggcaptur
elisa
figur
none
healthi
control
subject
detect
sar
figur
mean
optic
densiti
plu
sd
measur
nm
use
determin
cutoff
valu
igmcaptur
elisa
sensit
serolog
test
mean
optic
densiti
plu
sd
measur
nm
use
determin
cutoff
valu
iggcaptur
elisa
sensit
serolog
test
combin
result
igmand
iggcaptur
elisa
sampl
patient
would
detect
sensit
would
increas
figur
contrast
serum
sampl
obtain
healthi
control
subject
seroneg
figur
specif
test
healthi
control
subject
test
reactiv
serum
antibodi
patient
sar
use
epitopebas
synthet
peptid
contain
aa
residu
sarscov
detect
sampl
patient
sar
elisa
figur
contrast
serum
sampl
obtain
healthi
control
subject
seroneg
mean
optic
densiti
measur
nm
use
determin
cutoff
valu
sensit
specif
use
epitopebas
synthet
peptid
serolog
test
figur
analyz
antibodyrespons
kinet
use
elisa
patient
higher
sarscovspecif
antibodi
titer
patient
igm
antibodi
appear
day
diseas
onset
level
peak
day
figur
igg
antibodi
titer
detect
day
diseas
onset
level
increas
exponenti
day
figur
kinet
iga
antibodi
respons
similar
igg
iga
antibodi
titer
detect
day
diseas
onset
level
increas
exponenti
day
figur
patient
igm
antibodi
detect
day
diseas
onset
level
peak
day
figur
igg
antibodi
titer
detect
day
diseas
onset
level
increas
igm
b
igg
c
iga
e
f
respons
patient
measur
use
phage
clone
describ
materi
method
igm
igg
respons
addit
patient
sar
g
h
also
measur
use
phage
clone
describ
materi
method
control
phage
clone
react
serum
sampl
patient
sar
studi
kinet
antibodi
respons
use
phage
clone
synthet
peptid
background
elisa
increas
use
synthet
peptid
antigen
detect
human
igm
od
optic
densiti
nm
exponenti
day
figur
patient
level
iga
antibodi
titer
increas
exponenti
onset
diseas
day
figur
kinet
antibodi
respons
also
studi
patient
lower
sarscovspecif
antibodi
titer
figur
patient
test
seroneg
igm
day
onset
symptom
figur
patient
test
seroneg
igm
igg
day
respect
onset
diseas
figur
identif
viral
b
cell
epitop
import
understand
virusantibodi
interact
molecular
level
provid
inform
develop
virusspecif
serolog
diagnost
reagent
subunit
vaccin
first
studi
character
serotypespecif
b
cell
epitop
sarscov
use
phagedisplay
method
select
phagedisplay
peptid
sequenc
consensu
motif
proproasn
vallysilexasn
correspond
amino
acid
residu
ppn
vkidn
sarscov
respect
result
synthet
peptidebind
competitiveinhibit
assay
confirm
patient
sar
gener
antibodi
sarscov
also
detect
antibodi
serum
sampl
patient
sar
use
phagedisplay
epitopebas
peptid
antigen
tissu
cultur
electron
microscopi
ifa
test
pcr
amplif
specif
genom
sequenc
complet
genom
sarscov
provid
evid
novel
coronaviru
infect
patient
sar
use
phagedisplay
method
found
b
cell
epitop
antibodi
respons
patient
sar
correspond
sarscov
confirm
microbiolog
origin
sar
studi
align
phagedisplay
peptid
sequenc
publish
protein
sequenc
sever
virus
describ
materi
method
immunoposit
phage
clone
display
consensu
motif
ppn
correspond
amino
acid
residu
sarscov
tabl
gene
product
genbank
access
sarscov
orfla
polyprotein
contain
aa
residu
anoth
immunoposit
phage
clone
display
consensu
motif
vkixn
correspond
amino
acid
residu
sarscov
tabl
gene
product
genbank
access
sarscov
hypothet
transmembran
protein
contain
aa
residu
also
found
peptid
sequenc
immunoposit
phage
clone
ispyntivaklr
tabl
similar
amino
acid
residu
hmpv
lsplgalvacyk
consensu
sequenc
indic
boldfac
type
serum
sampl
patient
sar
detect
use
elisa
phage
clone
serum
sampl
patient
detect
phage
clone
figur
data
shown
find
suggest
sar
caus
sarscov
also
exclud
possibl
hmpv
infect
may
exacerb
diseas
patient
sar
correl
sar
hmpv
infect
need
investig
also
compar
phagedisplay
peptid
sequenc
refer
virus
repres
speci
group
coronavirus
similar
found
serum
sampl
patient
sar
accur
detect
use
elisa
phage
clone
synthet
peptid
figur
sensit
igmor
iggcaptur
elisa
alon
howev
igmand
iggcaptur
elisa
combin
serum
sampl
patient
sar
detect
sensit
increas
use
serolog
test
found
serum
sampl
healthi
adult
seroneg
yield
specif
healthi
control
subject
figur
epitopebas
synthet
peptid
correspond
amino
acid
residu
sarscov
detect
serum
sampl
patient
sar
elisa
nonreact
serum
sampl
healthi
adult
figur
sensit
specif
use
method
serolog
test
patient
sar
healthi
adult
blind
analysi
also
done
elisa
serum
sampl
patient
sar
detect
healthi
adult
found
seroneg
confirm
efficaci
mean
detect
diseas
data
shown
studi
antibodyrespons
kinet
patient
sar
antibodi
detect
day
onset
diseas
figur
igm
found
earlier
day
onset
symptom
patient
respect
figur
acut
sarscov
infect
igm
antibodi
appear
day
level
peak
day
onset
diseas
igg
antibodi
titer
detect
day
continu
increas
exponenti
day
figur
delay
induct
igm
igg
respons
sar
need
investig
extent
delay
may
explain
sever
sarscov
infect
experiment
approach
describ
studi
identifi
peptid
react
diseasespecif
antibodi
isol
b
cell
epitop
sarscov
confirm
proproasn
vallysilexasn
motif
crucial
peptid
antigenantibodi
bind
studi
antibodi
kinet
figur
found
peptid
abl
detect
patient
serum
sampl
convalesc
phase
sar
acut
phase
peptidebind
competitiveinhibit
assay
show
synthet
peptid
correspond
amino
acid
residu
sarscov
confirm
patient
sar
gener
antibodi
sarscov
figur
confirm
epitopebas
synthet
peptid
gener
antibodi
sarscov
gener
antibodi
peptid
serum
sampl
found
ifa
gener
antibodi
recogn
sarscovinfect
vero
cell
figur
prove
phagedisplay
epitop
immunogen
sarscov
also
studi
neutral
activ
antibodi
use
tcid
sarscov
neutral
activ
patient
antiserum
notabl
neutral
sarscov
observ
mous
serum
sampl
identif
neutral
epitop
use
spike
proteinpurifi
antibodi
current
investig
find
also
indic
b
cell
epitop
antibodi
linear
typic
b
cell
epitop
identifi
method
easili
recogniz
consensu
sequenc
often
correspond
peptid
sequenc
found
natur
antigen
epitop
use
studi
microbiolog
origin
develop
epitopebas
diagnost
reagent
immunogen
viral
infect
dissect
antibodi
respons
sar
phage
excel
immunogen
immun
mice
phage
particl
elicit
celldepend
respons
phagedisplay
epitop
antibodi
antigen
develop
sar
vaccin
consist
cocktail
phagedisplay
neutral
epitop
may
possibl
date
analyz
result
patient
ill
met
cdc
case
definit
probabl
sar
studi
serum
sampl
obtain
convalesc
patient
day
onset
diseas
investig
regard
applic
serolog
test
human
serum
sampl
progress
case
sar
specif
evalu
percentag
subclin
mild
infect
relationship
antibodi
respons
diseas
sever
serolog
diagnost
reagent
sar
highli
sensit
specif
conveni
need
develop
found
use
synthet
peptid
sar
diagnosi
rel
simpl
select
phage
clone
epitopebas
peptid
antigen
studi
highli
specif
serum
patient
sar
feel
may
use
develop
diagnost
prognost
reagent
also
understand
pathogenesi
sar
